I would add ACHN to my short list of HCV candidates.
I would not short it, but at the current valuation it’s clearly less appealing than it was when I recommended it to biomaven one month ago (#msg-63571059). In general, I refrain from shorting small-cap names that are not outright scams (and the outright scams are usually impossible to borrow for shorting).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”